Vincerx Pharma, INC DEF 14A proxy statements

A pharmaceutical company has again adjourned its special meeting, urging stockholders to approve a dissolution proposal to preserve potential distributions now estimated between $0.03 and $0.07 per share.

A pharmaceutical company has announced its board's approval for dissolution and liquidation, estimating a final distribution to stockholders of $0.04 to $0.08 per share, urging immediate approval to avoid further cost erosion.

Vincerx Pharma, Inc. has adjourned its Special Meeting of Stockholders until July 16, 2025, to secure votes for a crucial dissolution proposal, emphasizing that further delays will diminish potential stockholder distributions.

Vincerx Pharma, Inc. is seeking stockholder approval for its liquidation and dissolution by June 18, 2025, emphasizing that prompt action is critical to preserve any potential, albeit non-significant, distributions and enable capital loss recognition for U.S. holders.

Vincerx Pharma plans to liquidate and dissolve the company after failing to secure financing or strategic partnerships, with stockholders set to vote on the proposal.

Vincerx Pharma and Oqory, Inc. amend their merger term sheet, increasing the minimum value for Vincerx stockholders to $14.16 million and waiving the remaining $500,000 interim financing.

Vincerx Pharma and Oqory, Inc. highlight positive Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, and discuss their proposed strategic merger to advance the drug into Phase 3 trials.

Vincerx Pharma and Oqory have entered into a binding term sheet for a merger, aiming to create a combined company focused on advancing Oqory's antibody-drug conjugate (ADC) pipeline.

Vincerx Pharma is asking shareholders to approve a reverse stock split to increase its share price and maintain its Nasdaq listing.

Vincerx Pharma updates the terms of its proposed Repricing and Exchange Program, including adjustments to the vesting schedule for RSUs and the Repriced Option Retention Period.

Vincerx Pharma is asking stockholders to approve a one-time stock option repricing and exchange program aimed at incentivizing employees and reducing equity overhang.

Vincerx Pharma's upcoming annual meeting on May 23, 2024, will address the election of Class I directors, an amendment to the 2020 Stock Incentive Plan, and the ratification of the company's independent accounting firm.

Vincerx Pharma's upcoming annual meeting on May 23, 2024, will address the election of three Class I directors, an amendment to the 2020 Stock Incentive Plan, and ratification of the company's independent accounting firm.